Table 1 Presenting clinical and... | American Society of Hematology

Table 1

Presenting clinical and laboratory features of myeloid neoplasm and control cases

	AML	MDS	ET	PV	PMF	Control
No. of cases	10	10	12	10	24	16
Mean age, y (range)	56.1 (31-77)	60.8 (36-80)	64.3 (30-80)	58.5 (34-85)	65.5 (40-86)	52.5 (21-85)
Sex, %
Male	27.2	50	83.3	30	58.3	43.7
Female	72.8	50	16.67	70	41.7	56.3
Cellularity, %*	80 (10-100)	68 (60-90)	43 (35-60)	83 (40-100)	75 (50-100)	48 (25-85)
Fibrosis grade†	1	2	1	1	1	0
Grade 0	0	0	33.3	0	8.4	50
Grade 1	70	40	66.6	60	45.8	50
Grade 2	20	50	0	20	20.8	0
Grade 3	10	10	0	20	25	0
WBC count, × 10⁹/L*	63.8 (1.6-420)	3.2 (1.2-5.2)	8.2 (4.1-13.2)	11.4 (4.9-22.6)	12 (2.3-51.5)	9.1 (2.2-14.6)
Hb, g/L*	83.6 (64-95)	88 (62-142)	130.6 (102-146)	160 (100-210)	122 (81-150)	128 (88-159)
PLT count, × 10⁹/L*	52.1 (16-146)	107.8 (19-264)	737.8 (411-942)	292.9 (126-494)	463.5 (13-1218)	305.9 (143-762)

	AML	MDS	ET	PV	PMF	Control
No. of cases	10	10	12	10	24	16
Mean age, y (range)	56.1 (31-77)	60.8 (36-80)	64.3 (30-80)	58.5 (34-85)	65.5 (40-86)	52.5 (21-85)
Sex, %
Male	27.2	50	83.3	30	58.3	43.7
Female	72.8	50	16.67	70	41.7	56.3
Cellularity, %*	80 (10-100)	68 (60-90)	43 (35-60)	83 (40-100)	75 (50-100)	48 (25-85)
Fibrosis grade†	1	2	1	1	1	0
Grade 0	0	0	33.3	0	8.4	50
Grade 1	70	40	66.6	60	45.8	50
Grade 2	20	50	0	20	20.8	0
Grade 3	10	10	0	20	25	0
WBC count, × 10⁹/L*	63.8 (1.6-420)	3.2 (1.2-5.2)	8.2 (4.1-13.2)	11.4 (4.9-22.6)	12 (2.3-51.5)	9.1 (2.2-14.6)
Hb, g/L*	83.6 (64-95)	88 (62-142)	130.6 (102-146)	160 (100-210)	122 (81-150)	128 (88-159)
PLT count, × 10⁹/L*	52.1 (16-146)	107.8 (19-264)	737.8 (411-942)	292.9 (126-494)	463.5 (13-1218)	305.9 (143-762)

Values are mean (range).

Fibrosis grade is reported as median (%) of each grade. Fibrosis is evaluated according to Thiele et al.⁷